Savaysa is owned by Daiichi Sankyo Inc.
Savaysa contains Edoxaban Tosylate.
Savaysa has a total of 2 drug patents out of which 0 drug patents have expired.
Savaysa was authorised for market use on 08 January, 2015.
Savaysa is available in tablet;oral dosage forms.
The generics of Savaysa are possible to be released after 28 March, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7365205||DAIICHI SANKYO INC||Diamine derivatives|| |
(4 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9149532||DAIICHI SANKYO INC||Pharmaceutical composition|| |
(5 years from now)
|M||Aug 9, 2022|
Market Authorisation Date: 08 January, 2015
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic